Emyria Ltd (ASX:EMD) participated in this week’s Proactive Lifesciences Webinar with managing director Michael Winlo outlining progress of its data-backed drug development program.
Not only is Emyria pioneering new ways to collect, standardise and analyse dynamic patient data and clinical evidence, it is also engaged in developing new care models for patients with unmet needs using novel treatments that bring together patients, clinicians, researchers and medical innovators.